ATE175210T1 - Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp) - Google Patents

Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp)

Info

Publication number
ATE175210T1
ATE175210T1 AT91115080T AT91115080T ATE175210T1 AT E175210 T1 ATE175210 T1 AT E175210T1 AT 91115080 T AT91115080 T AT 91115080T AT 91115080 T AT91115080 T AT 91115080T AT E175210 T1 ATE175210 T1 AT E175210T1
Authority
AT
Austria
Prior art keywords
chicken
cnp
biologically active
derived peptide
new biologically
Prior art date
Application number
AT91115080T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Suntory Ltd
Hisayuki Matsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd, Hisayuki Matsuo filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE175210T1 publication Critical patent/ATE175210T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91115080T 1990-09-07 1991-09-06 Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp) ATE175210T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2238293A JP2977158B2 (ja) 1990-09-07 1990-09-07 トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）

Publications (1)

Publication Number Publication Date
ATE175210T1 true ATE175210T1 (de) 1999-01-15

Family

ID=17028039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91115080T ATE175210T1 (de) 1990-09-07 1991-09-06 Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp)

Country Status (8)

Country Link
US (1) US5338830A (de)
EP (1) EP0475291B1 (de)
JP (1) JP2977158B2 (de)
AT (1) ATE175210T1 (de)
DE (1) DE69130696T2 (de)
DK (1) DK0475291T3 (de)
ES (1) ES2127190T3 (de)
GR (1) GR3029628T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
CN1960758B (zh) 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
EP1743653A4 (de) 2004-03-31 2009-09-30 Kazuwa Nakao Zusammensetzung zur erhöhung der körpergrösse
EP1759001B1 (de) 2004-04-21 2011-04-13 Enobia Pharma Inc. Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX2017007392A (es) 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
WO2017022728A1 (ja) * 2015-07-31 2017-02-09 株式会社イギス Ｃｎｐ環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (de) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei jugendlichen und erwachsenen
EP3436052A4 (de) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. Behandlung von muskelschwäche mit alkalischen phosphatasen
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3600383A4 (de) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie (hpp) bei erwachsenen und jugendlichen
EP3773684A1 (de) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Herstellung von glycoproteinen
EP4291224A1 (de) 2021-02-12 2023-12-20 Alexion Pharmaceuticals, Inc. Alkalische phosphatasepolypeptide und verfahren zur verwendung davon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
DK0475291T3 (da) 1999-08-30
DE69130696D1 (de) 1999-02-11
JP2977158B2 (ja) 1999-11-10
EP0475291B1 (de) 1998-12-30
DE69130696T2 (de) 1999-06-10
JPH04120094A (ja) 1992-04-21
EP0475291A1 (de) 1992-03-18
GR3029628T3 (en) 1999-06-30
ES2127190T3 (es) 1999-04-16
US5338830A (en) 1994-08-16

Similar Documents

Publication Publication Date Title
ATE175210T1 (de) Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp)
ATE175211T1 (de) Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp)
DE68921850D1 (de) Reinigung von durch Verwendung von Doppelmetallcyanidkomplexkatalysatoren hergestellten Polyolen.
DE59304248D1 (de) Mehrstufenprozess zur Herstellung von thermoplastisch verarbeitbaren Polyurethan-Elastomeren
DE69300497D1 (de) Silberkatalysator zur Herstellung von Äthylenoxid.
DE69109746D1 (de) Verfahren zur Herstellung von Acrolein oder Methacrolein.
DE3750915D1 (de) Für Antitumor-Polypeptide kodierende DNS, die Polypeptide und diese Polypeptide enthaltenden Antitumor-Wirkstoffe.
DE3788939D1 (de) Verfahren zur Herstellung von Uretdionringen enthaltenden Polyurethanen.
NO895028L (no) Ny chimerisk transformerende vekstfaktor-beta.
DE69010171D1 (de) Mehrstufenverfahren zur Herstellung von Hexafluoropropylen.
DE69219590D1 (de) BPC-Peptide, deren Herstellung und Verwendung
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
DE59102062D1 (de) Verfahren zur biologischen Reinigung von Abluftströmen.
DK0544826T3 (da) Overlegne trombomodulinanaloger til farmaceutisk anvendelse
DE59308152D1 (de) Mehrstufenprozess zur Herstellung von thermoplastisch verarbeitbaren Polyurethan-Elastomeren
DE3873342D1 (de) Nicht-zylindrischer reaktor zur herstellung von furnace-russ.
ATE305044T1 (de) Lgmd- gen kodierend für einer calcium abhängigen protease
ATE221121T1 (de) Verwendung einer dna sequenz, kodierende für ein protein mit der fäligkeit oxalsäure abzubauen, zur genselektion
ATE133709T1 (de) Peroxidase-gen von mikrobischem ursprung
ATE94588T1 (de) Verfahren zur herstellung und reinigung von alpha-interferon.
ATE14126T1 (de) Verfahren zur herstellung von 2-acyl1,3,4,6,7,11b-2h-hexahydro-4-pyrazino(2,1a)isochinolinonen und zwischenprodukte.
ATE47880T1 (de) Vorlaeufer eines an dem c-ende amidierten peptids und dessen herstellung.
DE59008482D1 (de) Verfahren zur Herstellung von 2,4,5-Triamino-6-hydroxypyrimidin durch katalytische Hydrierung von 2,4-Diamino-6-hydroxy-5-nitrosopyrimidin.
DE3750624D1 (de) Durchlaufreaktor für Peptidsequenatoren.
ATE30148T1 (de) Verfahren zur herstellung von betahydroxipropions|ureamid.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee